(NASDAQ: PYXS) Pyxis Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.19%.
Pyxis Oncology's revenue in 2024 is $16,146,000.On average, 3 Wall Street analysts forecast PYXS's revenue for 2024 to be $946,023,000, with the lowest PYXS revenue forecast at $943,075,888, and the highest PYXS revenue forecast at $951,917,224. On average, 3 Wall Street analysts forecast PYXS's revenue for 2028 to be $1,776,872,857, with the lowest PYXS revenue forecast at $471,537,944, and the highest PYXS revenue forecast at $4,334,612,550.
In 2029, PYXS is forecast to generate $7,617,990,197 in revenue, with the lowest revenue forecast at $3,241,823,365 and the highest revenue forecast at $11,568,004,611.